EP2465950A3 - Mutations de K-RAS et traitement avec des anticorps anti-EGFR - Google Patents

Mutations de K-RAS et traitement avec des anticorps anti-EGFR Download PDF

Info

Publication number
EP2465950A3
EP2465950A3 EP12154109A EP12154109A EP2465950A3 EP 2465950 A3 EP2465950 A3 EP 2465950A3 EP 12154109 A EP12154109 A EP 12154109A EP 12154109 A EP12154109 A EP 12154109A EP 2465950 A3 EP2465950 A3 EP 2465950A3
Authority
EP
European Patent Office
Prior art keywords
ras mutations
egfr antibody
antibody therapy
methods
ras
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP12154109A
Other languages
German (de)
English (en)
Other versions
EP2465950B1 (fr
EP2465950A2 (fr
Inventor
Daniel Freeman
Todd Juan
Robert Radinsky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39689242&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP2465950(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Priority to SI200831873T priority Critical patent/SI2465950T1/sl
Priority to PL12154109T priority patent/PL2465950T3/pl
Publication of EP2465950A2 publication Critical patent/EP2465950A2/fr
Publication of EP2465950A3 publication Critical patent/EP2465950A3/fr
Application granted granted Critical
Publication of EP2465950B1 publication Critical patent/EP2465950B1/fr
Priority to HRP20171509TT priority patent/HRP20171509T1/hr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
EP12154109.8A 2007-03-13 2008-03-11 Mutations de K-RAS et traitement avec des anticorps anti-EGFR Active EP2465950B1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
SI200831873T SI2465950T1 (sl) 2007-03-13 2008-03-11 Mutacije K-ras in terapija s protitelesi anti-EGFR
PL12154109T PL2465950T3 (pl) 2007-03-13 2008-03-11 Mutacje k-ras oraz terapia przeciwciałem anty-egfr
HRP20171509TT HRP20171509T1 (hr) 2007-03-13 2017-10-09 K-ras mutacije i terapija anti-egfr antitijelom

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90694307P 2007-03-13 2007-03-13
EP08742061.8A EP2121989B2 (fr) 2007-03-13 2008-03-11 Mutations de kras et traitement avec des anticorps anti-egfr

Related Parent Applications (3)

Application Number Title Priority Date Filing Date
EP08742061.8A Division EP2121989B2 (fr) 2007-03-13 2008-03-11 Mutations de kras et traitement avec des anticorps anti-egfr
EP08742061.8A Division-Into EP2121989B2 (fr) 2007-03-13 2008-03-11 Mutations de kras et traitement avec des anticorps anti-egfr
EP08742061.8 Division 2008-03-11

Publications (3)

Publication Number Publication Date
EP2465950A2 EP2465950A2 (fr) 2012-06-20
EP2465950A3 true EP2465950A3 (fr) 2013-03-13
EP2465950B1 EP2465950B1 (fr) 2017-07-12

Family

ID=39689242

Family Applications (2)

Application Number Title Priority Date Filing Date
EP08742061.8A Active EP2121989B2 (fr) 2007-03-13 2008-03-11 Mutations de kras et traitement avec des anticorps anti-egfr
EP12154109.8A Active EP2465950B1 (fr) 2007-03-13 2008-03-11 Mutations de K-RAS et traitement avec des anticorps anti-EGFR

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP08742061.8A Active EP2121989B2 (fr) 2007-03-13 2008-03-11 Mutations de kras et traitement avec des anticorps anti-egfr

Country Status (21)

Country Link
US (3) US20080293055A1 (fr)
EP (2) EP2121989B2 (fr)
JP (1) JP2010521153A (fr)
AR (1) AR065687A1 (fr)
AU (1) AU2008226803A1 (fr)
CA (1) CA2680326A1 (fr)
CL (1) CL2008000717A1 (fr)
CY (2) CY1115333T1 (fr)
DK (2) DK2465950T3 (fr)
ES (2) ES2458626T5 (fr)
HR (2) HRP20140360T4 (fr)
HU (1) HUE033695T2 (fr)
LT (1) LT2465950T (fr)
MX (1) MX2009009787A (fr)
PE (1) PE20081880A1 (fr)
PL (2) PL2121989T5 (fr)
PT (2) PT2121989E (fr)
RS (2) RS56422B1 (fr)
SI (2) SI2465950T1 (fr)
TW (1) TW200902553A (fr)
WO (1) WO2008112269A2 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2620195A1 (fr) * 2005-08-24 2007-03-01 Bristol-Myers Squibb Company Marqueurs biologiques et procedes permettant de determiner la receptivite aux modulateurs du recepteur du facteur de croissance epidermique (egfr)
US8768629B2 (en) 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
CN101449162B (zh) 2006-05-18 2013-07-31 分子压型学会股份有限公司 确定针对病状的个性化医疗介入的系统和方法
PT2412828E (pt) * 2007-03-13 2013-08-02 Amgen Inc Mutações k-ras e b-raf e terapia com anticorpos anti-egfr
US8583380B2 (en) 2008-09-05 2013-11-12 Aueon, Inc. Methods for stratifying and annotating cancer drug treatment options
EP3181705A1 (fr) 2008-11-12 2017-06-21 Caris Life Sciences Switzerland Holdings GmbH Procédés et systèmes permettant d'utiliser des exosomes pour déterminer des phénotypes
US8502015B1 (en) 2009-07-06 2013-08-06 Transgenex Nanobiotech, Inc. Method of inducing cancer
CN102115782B (zh) * 2009-12-30 2014-06-18 北京雅康博生物科技有限公司 用于定量检测K-ras突变的试剂盒
JP5808349B2 (ja) 2010-03-01 2015-11-10 カリス ライフ サイエンシズ スウィッツァーランド ホールディングスゲーエムベーハー セラノーシスのためのバイオマーカー
US9469876B2 (en) 2010-04-06 2016-10-18 Caris Life Sciences Switzerland Holdings Gmbh Circulating biomarkers for metastatic prostate cancer
CN102869790B (zh) * 2010-04-12 2014-11-26 反应遗传有限公司 Kras引物和探针
IN2013MN00522A (fr) 2010-09-24 2015-05-29 Univ Leland Stanford Junior
US8628773B2 (en) 2011-04-07 2014-01-14 Amgen Inc. Antigen binding proteins
CN104039328B (zh) 2011-11-11 2018-10-09 米伦纽姆医药公司 对蛋白酶体抑制剂的反应的生物标记
US11913065B2 (en) 2012-09-04 2024-02-27 Guardent Health, Inc. Systems and methods to detect rare mutations and copy number variation
US20160040229A1 (en) 2013-08-16 2016-02-11 Guardant Health, Inc. Systems and methods to detect rare mutations and copy number variation
US10876152B2 (en) 2012-09-04 2020-12-29 Guardant Health, Inc. Systems and methods to detect rare mutations and copy number variation
CA2883901C (fr) 2012-09-04 2023-04-11 Guardant Health, Inc. Systemes et procedes pour detecter des mutations rares et une variation de nombre de copies
US20140199405A1 (en) * 2013-01-11 2014-07-17 Abraxis Bioscience, Llc Method for treating cancer based on mutation status of k-ras
SG11201507739TA (en) * 2013-03-19 2015-10-29 Toppan Printing Co Ltd Method for predicting sensitivity to egfr inhibitor
EP3524694B1 (fr) 2013-12-28 2020-07-15 Guardant Health, Inc. Procédés et systèmes de détection de variants génétiques
WO2015175705A1 (fr) * 2014-05-13 2015-11-19 Board Of Regents, The University Of Texas System Mutations géniques et altérations du nombre de copies de egfr, kras et met
WO2017106768A1 (fr) 2015-12-17 2017-06-22 Guardant Health, Inc. Procédés de détermination du nombre de copies du gène tumoral par analyse d'adn acellulaire
CN110357965A (zh) * 2019-06-24 2019-10-22 浙江大学 一种突变型kras特异性抗体及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007001868A1 (fr) * 2005-06-28 2007-01-04 Genentech, Inc. Mutations chez r-egf et kras
WO2007011702A2 (fr) * 2005-07-15 2007-01-25 The University Of North Carolina At Chapel Hill Utilisation d'inhibiteurs de recepteur egf pour prevenir ou traiter l'obesite

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
JP4124480B2 (ja) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
US5470705A (en) 1992-04-03 1995-11-28 Applied Biosystems, Inc. Probe composition containing a binding domain and polymer chain and methods of use
DE69322266T2 (de) 1992-04-03 1999-06-02 Perkin Elmer Corp Proben zusammensetzung und verfahren
KR20080059467A (ko) 1996-12-03 2008-06-27 아브게닉스, 인크. 복수의 ｖｈ 및 ｖｋ 부위를 함유하는 사람 면역글로불린유전자좌를 갖는 형질전환된 포유류 및 이로부터 생성된항체
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
WO2000055368A2 (fr) 1999-03-15 2000-09-21 Pe Corporation (Ny) Complexes sonde/modificateur de mobilite pour detection d'acide nucleique multiplex
JP2004507226A (ja) 2000-05-30 2004-03-11 ピーイー　コーポレイション　（エヌワイ） ライゲーションおよび増幅の組み合わせを用いて標的核酸を検出するための方法
US6503914B1 (en) * 2000-10-23 2003-01-07 Board Of Regents, The University Of Texas System Thienopyrimidine-based inhibitors of the Src family
US20040033543A1 (en) 2002-05-20 2004-02-19 Gisela Schwab Treatment of renal carcinoma using antibodies against the EGFr
EP2226396A1 (fr) 2003-05-30 2010-09-08 Genomic Health, Inc. Marqueurs d'expression génique utilisés en vue d'une réponse à des medicaments inhibiteurs de EGFR
CN101501211A (zh) 2004-03-31 2009-08-05 综合医院公司 测定癌症对表皮生长因子受体靶向性治疗反应性的方法
CA2569520C (fr) 2004-06-04 2023-03-14 Genentech, Inc. Mutations de kras destinees a identifier des tumeurs colorectales reagissant au cetuximab ou au panitumumab
EP1812601A2 (fr) * 2004-10-22 2007-08-01 Redpath Integrated Pathology, Inc. Expansion dynamique des suppressions genomiques et formulation de jeux de marqueurs moleculaires pour diagnostic integre de pathologie moleculaire et caracterisation des echantillons de tissus, de fluides cellulaires et de fluides purs
JP2008536493A (ja) 2005-04-01 2008-09-11 アムジエン・インコーポレーテツド 上皮増殖因子受容体遺伝子のコピー数
CN101155932A (zh) * 2005-04-14 2008-04-02 默克专利有限公司 基于在肿瘤组织中增加的egfr基因拷贝数的抗egfr抗体治疗
CA2620195A1 (fr) * 2005-08-24 2007-03-01 Bristol-Myers Squibb Company Marqueurs biologiques et procedes permettant de determiner la receptivite aux modulateurs du recepteur du facteur de croissance epidermique (egfr)
WO2007109571A2 (fr) * 2006-03-17 2007-09-27 Prometheus Laboratories, Inc. Procédés de prédiction et de suivi de la thérapie par l'inhibiteur de la tyrosine kinase
WO2008033442A2 (fr) * 2006-09-12 2008-03-20 The Board Of Trustees Of The Leland Stanford Junior University Méthodes et compositions permettant d'effectuer des réactions d'amplification multiplexées d'acides nucléiques, à faible bruit
PT2412828E (pt) * 2007-03-13 2013-08-02 Amgen Inc Mutações k-ras e b-raf e terapia com anticorpos anti-egfr

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007001868A1 (fr) * 2005-06-28 2007-01-04 Genentech, Inc. Mutations chez r-egf et kras
WO2007011702A2 (fr) * 2005-07-15 2007-01-25 The University Of North Carolina At Chapel Hill Utilisation d'inhibiteurs de recepteur egf pour prevenir ou traiter l'obesite

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
AMADO RAFAEL G ET AL: "Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer", JOURNAL OF CLINICAL ONCOLOGY, AMERICAN SOCIETY OF CLINICAL ONCOLOGY, vol. 26, no. 10, 1 April 2008 (2008-04-01), pages 1626 - 1634, XP009104317, ISSN: 0732-183X *
BENVENUTI SILVIA ET AL: "Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies", 20070315, 15 March 2007 (2007-03-15), XP002491315 *
CARAGLIA MICHELE ET AL: "EGF-R small inhibitors and anti-EGF-R antibodies: advantages and limits of a new avenue in anticancer therapy.", RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY JUN 2006, vol. 1, no. 2, June 2006 (2006-06-01), pages 209 - 222, XP009104857, ISSN: 1574-8928 *
CHUA YU JO ET AL: "Panitumumab", DRUGS OF TODAY, vol. 42, no. 11, November 2006 (2006-11-01), pages 711 - 719, XP002493245, ISSN: 1699-3993 *
CLAUDIA AUGELLO ET AL: "TP53 and p16INK4A, but not H-KI-Ras, are involved in tumorigenesis and progression of pleomorphic adenomas", JOURNAL OF CELLULAR PHYSIOLOGY, vol. 207, no. 3, 1 June 2006 (2006-06-01), pages 654 - 659, XP055051872, ISSN: 0021-9541, DOI: 10.1002/jcp.20601 *
EBERHARD D A ET AL: "Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib", JOURNAL OF CLINICAL ONCOLOGY, AMERICAN SOCIETY OF CLINICAL ONCOLOGY, vol. 23, no. 25, 1 September 2004 (2004-09-01), pages 5900 - 5909, XP002400936, ISSN: 0732-183X *
FRIDAY ET AL: "K-ras as a target for cancer therapy", BBA - REVIEWS ON CANCER, ELSEVIER SCIENCE BV, AMSTERDAM, NL, vol. 1756, no. 2, 25 November 2005 (2005-11-25), pages 127 - 144, XP005204727, ISSN: 0304-419X *
LIÈVRE ASTRID ET AL: "KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.", CANCER RESEARCH 15 APR 2006, vol. 66, no. 8, 15 April 2006 (2006-04-15), pages 3992 - 3995, XP002400937, ISSN: 0008-5472 *
PAO W ET AL: "KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib", PLOS MEDICINE 2005 US, vol. 2, no. 1, 2005, pages 0057 - 0061, XP002400935 *

Also Published As

Publication number Publication date
HRP20171509T1 (hr) 2017-11-17
PE20081880A1 (es) 2008-12-31
US20190048423A1 (en) 2019-02-14
DK2121989T3 (da) 2014-04-28
PT2465950T (pt) 2017-10-17
SI2121989T2 (sl) 2022-05-31
US11155876B2 (en) 2021-10-26
EP2465950B1 (fr) 2017-07-12
HRP20140360T1 (en) 2014-05-23
US20080293055A1 (en) 2008-11-27
US20120264129A1 (en) 2012-10-18
CL2008000717A1 (es) 2008-09-22
PT2121989E (pt) 2014-04-30
AU2008226803A1 (en) 2008-09-18
JP2010521153A (ja) 2010-06-24
CY1115333T1 (el) 2017-01-04
HRP20140360T4 (hr) 2022-06-10
AR065687A1 (es) 2009-06-24
LT2465950T (lt) 2017-10-10
PL2465950T3 (pl) 2017-12-29
DK2465950T3 (en) 2017-10-09
US10030270B2 (en) 2018-07-24
PL2121989T3 (pl) 2014-07-31
RS53265B (en) 2014-08-29
EP2121989B2 (fr) 2022-03-09
ES2458626T3 (es) 2014-05-06
PL2121989T5 (pl) 2023-03-06
WO2008112269A2 (fr) 2008-09-18
ES2635051T3 (es) 2017-10-02
SI2465950T1 (sl) 2017-11-30
DK2121989T4 (da) 2022-06-20
EP2121989B1 (fr) 2014-01-22
EP2121989A2 (fr) 2009-11-25
RS53265B2 (sr) 2022-06-30
WO2008112269A3 (fr) 2008-11-20
MX2009009787A (es) 2009-09-22
EP2465950A2 (fr) 2012-06-20
RS56422B1 (sr) 2018-01-31
HUE033695T2 (en) 2017-12-28
CA2680326A1 (fr) 2008-09-18
TW200902553A (en) 2009-01-16
SI2121989T1 (sl) 2014-06-30
CY1119112T1 (el) 2018-02-14
ES2458626T5 (es) 2022-04-29

Similar Documents

Publication Publication Date Title
EP2465950A3 (fr) Mutations de K-RAS et traitement avec des anticorps anti-EGFR
WO2008112274A3 (fr) Mutations de k-ras et de b-raf et thérapie utilisant des anticorps anti-egfr
ZA200709780B (en) Anti-EGFR antibody therapy based on an increased copy number of the EGFR gene in tumor tissues
IL180997A0 (en) Diagnostic methods and kits utilizing platelet biomarkers for cancer
WO2007103770A8 (fr) Compositions et procedes pour l'analyse du cancer du rein
EP2230254A3 (fr) Combinaisons thérapeutiques d'anticorps anti-igfr1
WO2009015284A8 (fr) Protéines de liaison à un antigène de récepteur d'il-18
IL232904A0 (en) Cutaneous preparations for constricting blood vessels and methods for protecting cells during chemotherapy and radiotherapy against cancer
WO2007115045A3 (fr) Diagnostics et traitements de tumeurs
IL177346A0 (en) Compositions and methods for characterizing, regulating, diagnosing, and treating cancer
EP2192132A3 (fr) Anticorps et partenaires de liaison anti-il-20, anti-il-22 et anti-il-22ra, et methodes d'utilisation de ces anticorps et partenaires de liaison dans des processus inflammatoires
UA96139C2 (uk) Антитіло до нейропіліну-1 (nrp1)
EP2631248A3 (fr) Traitement de tumeurs à l'aide d'un anticorps anti-L1 spécifique
IL190537A0 (en) Egfr dependent modulation of chemokine expression and influence on therapy and diagnosis of tumors and side effects thereof
WO2008073899A3 (fr) Compositions associées à prrg4 et procédés d'utilisation de celles-ci dans des procédés de diagnostic de tumeur
IL211255A0 (en) Cop1 molecules and uses thereof
WO2004078938A3 (fr) Polypeptides et anticorps derives de cellules de leucemie lymphocytique chronique et utilisations correspondantes
EP1776470A4 (fr) Reactifs, kits et procedes pour l' immunodetection d' epitopes sur des molecules
MX2010008025A (es) Anticuerpos ron y usos de los mismos.
WO2005113831A3 (fr) Biomarqueurs pour la sclerose en plaques et procedes d'utilisation correspondants
BRPI0407680A (pt) métodos para diagnóstico de cáncer e diminuição de metástase por células cancerosas
EA200970884A1 (ru) Способы лечения рака путем введения комбинаций человеческого интерлейкина ил-18
WO2003066663A3 (fr) Peptides utilises pour reconnaitre et cibler des tumeurs de cellules gliales
WO2005033133A3 (fr) Polynucleotides codant pour des nouveaux polypeptides erbb-2; trousses et methodes d'utilisation
SG157321A1 (en) Anti-met monoclonal antibody, fragments and derivatives thereof for use in tumor diagnosis, corresponding compositions and kits

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AC Divisional application: reference to earlier application

Ref document number: 2121989

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA MK RS

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA MK RS

RIC1 Information provided on ipc code assigned before grant

Ipc: C12Q 1/68 20060101AFI20130207BHEP

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1172372

Country of ref document: HK

17P Request for examination filed

Effective date: 20130912

RAX Requested extension states of the european patent have changed

Extension state: RS

Payment date: 20130912

Extension state: MK

Payment date: 20130912

Extension state: AL

Payment date: 20130912

Extension state: BA

Payment date: 20130912

RBV Designated contracting states (corrected)

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

17Q First examination report despatched

Effective date: 20140120

RIN1 Information on inventor provided before grant (corrected)

Inventor name: FREEMAN, DANIEL

Inventor name: RADINSKY, ROBERT

Inventor name: JUAN, TODD

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20170126

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AC Divisional application: reference to earlier application

Ref document number: 2121989

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA MK RS

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 908365

Country of ref document: AT

Kind code of ref document: T

Effective date: 20170715

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602008051128

Country of ref document: DE

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: RO

Ref legal event code: EPE

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: KIRKER AND CIE S.A., CH

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2635051

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20171002

REG Reference to a national code

Ref country code: HR

Ref legal event code: TUEP

Ref document number: P20171509

Country of ref document: HR

Ref country code: DK

Ref legal event code: T3

Effective date: 20171003

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Ref document number: 2465950

Country of ref document: PT

Date of ref document: 20171017

Kind code of ref document: T

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20171004

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: EE

Ref legal event code: FG4A

Ref document number: E014321

Country of ref document: EE

Effective date: 20170927

REG Reference to a national code

Ref country code: HR

Ref legal event code: T1PR

Ref document number: P20171509

Country of ref document: HR

REG Reference to a national code

Ref country code: NO

Ref legal event code: T2

Effective date: 20170712

REG Reference to a national code

Ref country code: HU

Ref legal event code: AG4A

Ref document number: E033695

Country of ref document: HU

REG Reference to a national code

Ref country code: SK

Ref legal event code: T3

Ref document number: E 25409

Country of ref document: SK

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 11

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20170402583

Country of ref document: GR

Effective date: 20180309

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602008051128

Country of ref document: DE

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20180413

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20171509

Country of ref document: HR

Payment date: 20190213

Year of fee payment: 12

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20171509

Country of ref document: HR

Payment date: 20200212

Year of fee payment: 13

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20171509

Country of ref document: HR

Payment date: 20210305

Year of fee payment: 14

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20171509

Country of ref document: HR

Payment date: 20220310

Year of fee payment: 15

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20171509

Country of ref document: HR

Payment date: 20230228

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CY

Payment date: 20230222

Year of fee payment: 16

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230523

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20230403

Year of fee payment: 16

Ref country code: CH

Payment date: 20230401

Year of fee payment: 16

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20171509

Country of ref document: HR

Payment date: 20240227

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 20240220

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GR

Payment date: 20240222

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IS

Payment date: 20240305

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LT

Payment date: 20240220

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20240220

Year of fee payment: 17

Ref country code: IE

Payment date: 20240222

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20240222

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: MC

Payment date: 20240226

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: RO

Payment date: 20240305

Year of fee payment: 17

Ref country code: HU

Payment date: 20240311

Year of fee payment: 17

Ref country code: FI

Payment date: 20240223

Year of fee payment: 17

Ref country code: EE

Payment date: 20240221

Year of fee payment: 17

Ref country code: DE

Payment date: 20240220

Year of fee payment: 17

Ref country code: CZ

Payment date: 20240226

Year of fee payment: 17

Ref country code: BG

Payment date: 20240227

Year of fee payment: 17

Ref country code: PT

Payment date: 20240221

Year of fee payment: 17

Ref country code: GB

Payment date: 20240220

Year of fee payment: 17

Ref country code: SK

Payment date: 20240228

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SI

Payment date: 20240301

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: TR

Payment date: 20240301

Year of fee payment: 17

Ref country code: SE

Payment date: 20240220

Year of fee payment: 17

Ref country code: PL

Payment date: 20240220

Year of fee payment: 17

Ref country code: NO

Payment date: 20240222

Year of fee payment: 17

Ref country code: MT

Payment date: 20240228

Year of fee payment: 17

Ref country code: LV

Payment date: 20240220

Year of fee payment: 17

Ref country code: IT

Payment date: 20240220

Year of fee payment: 17

Ref country code: HR

Payment date: 20240227

Year of fee payment: 17

Ref country code: FR

Payment date: 20240220

Year of fee payment: 17

Ref country code: DK

Payment date: 20240220

Year of fee payment: 17

Ref country code: BE

Payment date: 20240220

Year of fee payment: 17